Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
501-520 of 2,251 trials

Non-Small-Cell Lung Cancer: Amivantamab Treatment Study

We are studying the effects of a new antibody treatment, amivantamab, alone and with chemotherapy for patients with early-stage lung cancer. This research aims to see if it helps before surgery and how it affects tumor characteristics.

Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutation>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Axial Spondyloarthritis: Imaging with Technetium-labeled Certolizumab Pegol

We are studying whether a new imaging method can improve treatment decisions for people with axial spondyloarthritis. This may help doctors better assess disease activity and predict treatment responses.

Axial Spondyloarthritis>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesInternal MedicineRheumatology

Advanced Non-Small Cell Lung Cancer: OSIBOOST 2 Study

We are testing a modified dosing strategy of osimertinib, with or without a booster drug, for patients with advanced EGFR mutated NSCLC. This study aims to improve treatment cost-effectiveness and reduce side effects while maintaining effectiveness.

Non-Small Cell Lung Cancer with an EGFR Mutation≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementOncologyPulmonology

Fosigotifator for Vanishing White Matter Disease

We are exploring the safety and tolerability of Fosigotifator in adults and children with Vanishing White Matter Disease. This study aims to understand how the body handles this new treatment.

Vanishing White Matter Disease>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Prostate Cancer: Abiraterone and Oxycodone Study

We are investigating how abiraterone affects the metabolism of oxycodone in men with prostate cancer. This may help improve pain management for patients using these medications.

Prostate Cancer≤3 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesInternal MedicineOncologyUrology

HER2-Positive Biliary Tract Cancer: GemCis with Trastuzumab and Pembrolizumab

We are studying a combination of treatments for people with HER2-positive biliary tract cancer to see if it improves response rates and overall survival. This trial aims to assess both the effectiveness and safety of the treatment.

Cholangiocarcinoma and Gallbladder Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

End-Stage Renal Disease: Rivaroxaban Dosing Study

We are studying different doses of rivaroxaban to find the safest option for patients on chronic hemodialysis. The trial will also look at the risk of bleeding with each dose.

Chronic Hemodialysis≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineNephrology

Graft-versus-Host Disease: MC0518 Treatment Study

We are testing a new treatment, MC0518, for adults and adolescents with steroid-refractory acute graft-versus-host disease after stem cell transplantation. The study aims to see if it works better than the best available therapy and how it affects patients' quality of life.

Steroid Refractory Acute Graft Versus Host DiseaseConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Lung Cancer Treatment: Telisotuzumab Vedotin vs. Docetaxel

We are studying a new intravenous treatment for adults with previously treated non-squamous non-small cell lung cancer. The trial aims to see if it improves survival and quality of life compared to standard therapy.

Non-Squamous Non-Small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Tumor Treatment: Botensilimab and Balstilimab Study

We are studying a new combination of immune therapies for patients with specific tumor types to see if it can reduce tumor size before surgery. This trial aims to improve treatment effectiveness and safety.

dMMR Tumors≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncology

Early Breast Cancer: Elacestrant and Ribociclib Study

We are testing a new treatment combination of elacestrant and ribociclib for patients with hormone-sensitive early breast cancer. The goal is to see if this combination works better than standard therapies before surgery.

Hormone Receptor Positive HER2 Negative Breast Cancer6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Lung Cancer Treatment: Livmoniplimab and Budigalimab

We are studying a new combination of drugs for adults with untreated metastatic non-squamous non-small cell lung cancer. The goal is to see if this combination works better than a standard treatment with pembrolizumab and chemotherapy.

Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Immune Thrombocytopenia: New Combination Therapy

We are studying a new treatment combining four medications for patients with immune thrombocytopenia. The trial will evaluate its effectiveness, safety, and impact on quality of life.

Immune ThrombocytopeniaEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyInfectious Diseases

B-cell Non-Hodgkin Lymphoma: Surovatamig Treatment Study

We are studying how well surovatamig works and its safety for adults with certain types of blood cancers. This trial aims to learn more about its effects on lymphoma and patient experiences.

Relapsed or Refractory Non-Hodgkin Lymphoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Cardiovascular Disease: New Care Strategies for Type 1 Diabetes

We are testing a new care approach to reduce cardiovascular disease risk in people with type 1 diabetes. This study also evaluates the safety of a medication called finerenone in this high-risk group.

Type 1 Diabetes>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteCardiologyEndocrinologyInternal Medicine

Baricitinib for Uveitis in Children with Juvenile Idiopathic Arthritis

We are studying whether the oral medication baricitinib is safe and effective for children aged 2 to under 18 with active uveitis linked to juvenile idiopathic arthritis. This research aims to improve treatment options for these young patients.

UveitisConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOphthalmologyRheumatology

Epcoritamab for Relapsed Primary CNS Lymphoma

We are studying the effects of epcoritamab in patients with relapsed primary diffuse large B-cell lymphoma of the CNS who have been treated with lenalidomide and rituximab. The trial aims to evaluate its effectiveness, safety, and impact on quality of life.

Relapsed and Refractory Primary Diffuse Large B-Cell Lymphoma of the CNS>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyNeurologyOncology

Asthma Management: BIRDIE Trial

We are exploring if we can safely extend the dosing schedule of two asthma medications for patients with severe eosinophilic and T2-high asthma. This study looks at whether this approach maintains asthma control.

Severe AsthmaConfirmation phase (III)No PlaceboStandard MedicinesAllergologyPulmonology

B-Cell Acute Lymphoblastic Leukemia: AZD0486 Study

We are investigating whether AZD0486 is safe and effective for adolescents and adults with relapsed or refractory B-cell acute lymphoblastic leukemia. This trial aims to understand how well it works compared to existing treatments.

B-Cell Acute Lymphoblastic LeukaemiaSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Juvenile Idiopathic Arthritis: Filgotinib Study

We are studying how the medication filgotinib works in children and teens with juvenile idiopathic arthritis. The trial will also evaluate its safety and how well young patients accept the medication.

Juvenile Idiopathic Arthritis≤3 monthsSafety phase (I)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPediatricsRheumatology